1,916 material Form 8-K filings that 1,609 companies we cover made with the SEC in July 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Sunbelt Rentals Holdings completed the sale of $450 million of 4.950% senior notes due 2030 and $750 million of 5.650% senior notes due 2036 on July 14, 2026. The notes add $1.2 billion of long-term debt, with interest payable semi-annually starting February 12, 2027, and rank equal with the company's existing and future senior debt.
2030 Notes: $450 million at 4.950%, issued at 99.627%, maturing August 12, 2030
2036 Notes: $750 million at 5.650%, issued at 99.048%, maturing August 12, 2036
Holders may require repurchase at 101% of principal plus accrued interest upon a change in control triggering event
Notes are jointly and severally guaranteed by domestic subsidiaries that guarantee the revolving credit facility; BNY Mellon serves as trustee
Pentair said preliminary second-quarter 2026 sales are about $930 million, down 17% from its prior guidance of up about 1%, mainly because of Pool channel inventory destocking. It cut full-year 2026 adjusted EPS guidance to $4.60 to $4.80 from $5.30 to $5.40, and said CFO Nicholas Brazis resigned on July 10, 2026, with Robert Fishman named interim CFO.
Q2 2026 preliminary sales of about $930 million, down 17% versus prior guidance of up about 1%
Q2 2026 adjusted EPS of about $1.12 versus prior guidance of $1.47 to $1.50; GAAP EPS of about $0.80
Full-year 2026 adjusted EPS guidance cut to $4.60 to $4.80 from $5.30 to $5.40; full-year sales now expected down 4% to 7%
CFO Nicholas Brazis resigned July 10, 2026; Robert Fishman appointed interim CFO with a $125,000 monthly salary
SBC Medical received a Nasdaq notice that it no longer meets independent director and audit committee rules after Mike Sayama chose not to seek re-election. Stockholders also approved charter amendments and the board adopted amended bylaws, including a majority-vote resignation policy for uncontested director elections. The company says the notice has no immediate effect on its listing, but it must restore compliance within the cure period.
Nasdaq notice received July 10, 2026; board has four members, two of them independent, and the audit committee has two independent directors
Cure period ends at the earlier of the next annual meeting or July 9, 2027, or January 5, 2027 if the next annual meeting is held before that date
Restated charter effective July 9, 2026; amended and restated bylaws adopted July 8, 2026
Stockholders elected four directors and ratified MaloneBailey, LLP as auditor for fiscal 2026 with 93,954,650 votes for
Anika Therapeutics entered into a Fifth Amendment to its revolving credit agreement with Bank of America, N.A., extending the senior revolving line of credit to a $50.0 million facility maturing July 10, 2031. The company may request up to an additional $50.0 million in commitments, for a maximum of $100.0 million, subject to lender approval. The filing does not report any borrowings under the facility, and the amendment adds lender liens on substantially all assets and financial covenants that shareholders should note.
Senior revolving line of credit of $50.0 million, maturing July 10, 2031, with an option for up to $100.0 million aggregate commitments
Interest at SOFR plus 0.25% to 1.25%, based on the consolidated leverage ratio; commitment fee of 0.20% to 0.30% per annum on unused amounts
Lenders have a first priority lien on substantially all assets, except certain intangible assets; covenants cover leverage and interest coverage ratios
Amendment dated July 10, 2026; 8-K filed July 14, 2026 with Exhibit 10.1 attached
Research Alliance Corporation IV, a blank check company focused on healthcare, closed its initial public offering on July 14, 2026, selling 7,500,000 Class A ordinary shares at $10.00 each for $75 million in gross proceeds. The IPO and a $2.75 million private placement to the sponsor funded a trust account of $75 million for public shareholders. The filing says the company must complete an initial business combination within 24 months of the IPO closing, or liquidate.
Closed IPO of 7,500,000 Class A ordinary shares at $10.00 per share on July 14, 2026, for gross proceeds of $75,000,000 before underwriting discounts and offering expenses.
Sponsor Research Alliance Holdings IV LLC bought 275,000 private placement shares at $10.00 each, for total proceeds of $2,750,000.
$75,000,000 of net proceeds and private placement funds, including a $2,250,000 underwriter deferred commission, were deposited in a trust account with Continental Stock Transfer & Trust Company as trustee.
Alan Musso and John Maslowski were appointed to the board on July 10, 2026, and each received 30,000 Class B ordinary shares from the sponsor as compensation.
Aehr Test Systems reported fourth-quarter fiscal 2026 revenue of $18.8 million and GAAP net income of $1.4 million, compared with a net loss a year earlier, while full-year revenue fell to $50.0 million and the full-year GAAP net loss widened to $7.1 million. The company guided fiscal 2027 revenue to $130 million to $150 million, supported by an effective backlog of $100.6 million, which it said represents 2.6x to 3.0x fiscal 2026 revenue.
Q4 fiscal 2026 revenue was $18.8 million, up from $14.1 million a year earlier; GAAP net income was $1.4 million, or $0.04 per diluted share, versus a loss of $(0.10) per share.
Fiscal 2026 revenue was $50.0 million, down from $59.0 million; GAAP net loss was $(7.1) million, or $(0.23) per diluted share, versus $(3.9) million in fiscal 2025.
Record quarterly bookings of $60.7 million; effective backlog of $100.6 million as of the filing date.
Fiscal 2027 revenue guidance of $130 million to $150 million, implying approximately 160% to 200% year-over-year growth; cash, cash equivalents and restricted cash were $116.5 million at May 29, 2026.
Allstate said Christian Lown will become Executive Vice President and Chief Financial Officer on August 3, 2026, succeeding Jess Merten, who became President of Property-Liability in October 2025. John Dugenske has served as interim CFO and will continue in that role until Lown starts. The filing sets Lown's pay package, including a $875,000 base salary and a $2,000,000 sign-on bonus, which matters to shareholders as a senior finance leadership change.
Christian Lown starts as EVP and CFO effective August 3, 2026, reporting to Chair, President and CEO Tom Wilson.
Lown's prior roles include CFO of CoStar Group (July 2024 to July 2026) and CFO of Freddie Mac (June 2020 to June 2024).
Compensation: $875,000 annual base salary, annual target cash incentive of 200% of salary, and equity incentive of 375% of salary.
Sign-on package: $2,000,000 one-time cash bonus and $4,100,000 in RSUs vesting ratably over three years.
AutoZone completed the sale of $850 million in aggregate principal of 4.950% senior notes maturing July 15, 2031, on July 14, 2026. The notes are senior unsecured debt, so the company takes on new borrowing that must be repaid with interest.
Principal amount of $850 million; fixed interest rate of 4.950% per year, paid semi-annually on January 15 and July 15, starting January 15, 2027
Notes mature July 15, 2031 and rank equally with the company's other senior unsecured liabilities
Issued under an August 8, 2003 indenture with Regions Bank as successor trustee, and sold under a shelf registration filed July 7, 2026
Company may redeem the notes early, and holders may require repurchase after a change of control triggering event
Equinix said Chief Business Officer Jon Lin will separate from the company effective July 18, 2026, and that he will receive severance payments and benefits under the Executive Severance Plan, subject to a release of claims. The company has spread his responsibilities across its existing senior leadership and expects to announce a new Chief Product Officer soon.
Jon Lin, Chief Business Officer, separates from Equinix effective July 18, 2026
Severance payments and benefits under the Executive Severance Plan, subject to a release of claims
Responsibilities distributed across existing senior leadership team under a transition plan
New Chief Product Officer announcement expected in the near future
Ulta Beauty said board member Kelly Garcia will become its Chief Technology Officer effective August 31, 2026, and will resign from the board on that date. The change moves a board member into a senior executive role and is a leadership change rather than a financial result.
Kelly Garcia, a board member since 2022, is appointed Chief Technology Officer effective August 31, 2026.
Garcia resigns from the Board of Directors effective on his CTO start date.
Garcia previously served as Executive Vice President and CTO of Domino's Pizza since July 2012.
The filing contains no financial results or guidance.
PVH Corp. said its Employment Agreement with Alexis Rollier, currently Global Chief Operating Officer and Global Chief Financial Officer at Sephora, makes him CFO. He joins in early September 2026 and replaces Melissa Stone, who has served as interim CFO since January 1, 2026. The filing sets his base salary at $850,000 and details equity and severance terms, which matter to shareholders as they define the cost and terms of the company's new finance leader.
Alexis Rollier, age 57, will join PVH as CFO in early September 2026, succeeding interim CFO Melissa Stone through September 7, 2026.
Initial base salary is $850,000, with a target bonus of 100% of base salary and a 2027 equity grant of about $1,150,000 in PSUs plus about $1,150,000 in RSUs.
A $375,000 make-whole cash advance and a make-whole RSU award with a grant date value of $275,000 replace awards he forfeits at his current employer.
Severance is two times base salary plus target bonus if terminated without cause or for good reason, with higher protection within two years after a change in control.
Domino's Pizza appointed Michael C. Creedon, Jr. and Anneliese Olson to its board, effective July 15, 2026, expanding the board from eight to ten directors. The board also named Corie S. Barry lead independent director, replacing Richard L. Federico, who stays on the board as Audit Committee chairman. The filing also discloses that Chief Technology and Data Officer Kelly E. Garcia will resign effective August 28, 2026, and the company has started a search for a successor.
Michael C. Creedon, Jr. (Dollar Tree CEO) and Anneliese Olson (HP Inc. President, Imaging, Printing and Solutions) join the board effective July 15, 2026, and both join the Audit Committee
Corie S. Barry, a director since July 2018, replaces Richard L. Federico as Lead Independent Director
Executive Vice President and Chief Technology and Data Officer Kelly E. Garcia resigns effective August 28, 2026, to accept another executive position outside the company
Kestra Medical reported fiscal fourth-quarter 2026 revenue of $28.6 million, up 66%, and gave fiscal 2027 revenue guidance of $137 million, 44% above fiscal 2026. On July 10, 2026, it also entered a five-year senior secured term loan facility of up to $200.0 million, with $75.0 million funded at closing and used to repay its prior loan, which matters to shareholders because it adds debt secured by substantially all company assets.
Fiscal 4Q26 revenue was $28.6 million, up 66%, and gross margin was 54.8% versus 44.3% a year earlier.
FY27 revenue guidance is $137 million, compared with FY26 revenue of $95.1 million.
GAAP net loss was $38.8 million for the quarter versus $51.1 million a year earlier, but $131.6 million for the full year versus $113.8 million in FY25.
The July 10, 2026 loan has a $200.0 million facility, matures July 10, 2031, and requires at least $20.0 million in minimum liquidity.
Fortrea Holdings said Chief Accounting Officer Robert Parks will resign effective August 7, 2026, to pursue an opportunity outside the contract research industry, and that Vice President of Accounting Carrie Russell will serve as interim principal accounting officer. The filing also details the transition of CFO Jill McConnell, who will remain employed through September 8, 2026, with severance of $1,017,500 if she stays through that date. The company states Parks' decision was not the result of any disagreement over operations, policies, or accounting practices.
Robert A. Parks informed the company on July 8, 2026, of his resignation as Chief Accounting Officer and principal accounting officer, effective August 7, 2026.
Carrie Russell, Vice President of Accounting since August 2024, becomes interim principal accounting officer and interim Chief Accounting Officer, receiving a one-time $20,000 bonus plus $10,000 per month.
CFO Jill McConnell stays through September 8, 2026, with severance of $1,017,500 paid in two installments of $508,750, and a consulting agreement runs through March 8, 2027.
Repay Holdings agreed on July 13, 2026 to a cooperation agreement with PCP Managers II, L.P., an affiliate of one of its largest stockholders, and expanded its board from six to seven members. Zachary F. Sadek, a Senior Partner at Parthenon Capital Partners, was appointed to the board effective July 13, 2026, and the company agreed to nominate him for election at its 2027 annual meeting. The filing contains no financial results, so the change is a governance development rather than a measure of business performance.
Board size increased from six to seven members; Zachary F. Sadek appointed effective July 13, 2026.
Sadek's initial term expires at the 2027 annual meeting; the company agreed to nominate him for election there.
The agreement includes customary standstill and confidentiality terms that remain in effect until the earlier of 30 days after Sadek leaves the board or the first day after the 2027 annual meeting concludes.
The company says six of seven directors now qualify as independent under NASDAQ guidelines.
JPMorgan Chase reported second-quarter 2026 net income of $21.2B and diluted EPS of $7.70, up from $6.2B and $2.46 a year earlier, with managed revenue of $58.0B up 27% year over year. The results include a $4.6B net gain tied to Visa shares and $1.0B of equity investment gains; excluding these significant items, net income was $16.9B and EPS was $6.14. The Firm also raised its full-year 2026 adjusted expense outlook to about $107.5B, citing higher volume- and revenue-related expenses.
Net income $21.2B and EPS $7.70 for 2Q26; excluding significant items, net income $16.9B and EPS $6.14
Managed revenue $58.0B, up 27% YoY; expense $27.3B, up 15% YoY
Significant items: $4.6B net gain related to Visa shares and $1.0B of equity investment gains
FY2026 adjusted expense outlook of about $107.5B, increased from prior outlook; FY2026 net interest income outlook about $105.5B
Citigroup reported second-quarter 2026 net income of $5.8 billion, or $3.15 per diluted share, up from $4.0 billion, or $1.96 per share, a year earlier, on revenues of $24.8 billion, up 14%. The company said it will raise its planned dividend by 12% and has launched a $30 billion buyback plan, which the filing presents as a way to return more capital to shareholders.
Q2 2026 revenues of $24.8 billion, up 14% from $21.7 billion in Q2 2025
Diluted EPS of $3.15 versus $1.96 in the prior-year quarter, helped by a lower share count from repurchases
Planned dividend to increase 12% and a $30 billion buyback plan launched
Common Equity Tier 1 capital ratio of 12.8%, up from 12.7% at the end of the prior quarter
Ligand Pharmaceuticals completed its merger with XOMA Royalty on July 14, 2026, paying $39.00 per share in cash plus one contingent value right (CVR) per share, for a total equity value of approximately $739 million. In connection with the closing, Ligand entered an amended credit agreement providing a $125.0 million revolving credit facility maturing September 12, 2028. Ligand expects the deal to be immediately accretive, but CVR holders may receive no payment, depending on the outcome of pending litigation at XOMA Royalty.
Consideration: $39.00 per XOMA Royalty share in cash plus one CVR per share, with total equity value of approximately $739 million
Ligand expects the deal to add approximately $0.50 per share to projected 2026 adjusted EPS and $1.50 per share to projected 2027 adjusted EPS
Amended Credit Agreement provides a $125.0 million revolving credit facility maturing September 12, 2028, secured by certain collateral and guaranteed by material domestic subsidiaries
Ligand will provide an updated 5-year outlook at its Investor Day on December 8, 2026
California Resources Corporation said in a preliminary, unaudited update that its realized oil price for the three months ended June 30, 2026 was $76.50 per barrel after derivative settlements, versus $91.64 before them. The company estimates a $190 million loss from commodity derivatives for the quarter, and it warned that final results may differ and that the figures are not a quarterly earnings estimate.
Realized oil price with derivative settlements was $76.50 per barrel, compared with $91.64 without them.
Brent averaged $96.87 per barrel and WTI $92.79 per barrel for the quarter.
Estimated derivative loss of $190 million, including $164 million on commodity sales derivatives and $26 million on natural gas purchase derivatives.
The data is preliminary and unaudited and does not reflect all adjustments; the filing gives no earnings or revenue figures.
First Bancorp (Nasdaq: FBNC) signed a merger agreement to acquire First Carolina Bancshares Corporation, parent of Carolina Bank & Trust of Florence, South Carolina, in a deal with an aggregate value of $166 million. The filing says the deal is expected to close in the fourth quarter of 2026 or early in the first quarter of 2027, subject to First Carolina shareholder approval and regulatory approvals, and that the companies expect First Bancorp's quarterly earnings release on July 22, 2026 to be in line with market expectations.
Consideration to First Carolina shareholders: 14.5340 First Bancorp shares plus $294.94 in cash per First Carolina share, based on First Bancorp's $64.22 share price as of July 13, 2026
Total consideration includes 1,967,017 First Bancorp shares and $40 million in cash
Carolina Bank & Trust had approximately $831 million in assets, according to the press release
Under certain circumstances, First Carolina may owe First Bancorp a $6.4 million termination fee; the agreement can be terminated if the merger is not completed by June 30, 2027
Syndax Pharmaceuticals held an R&D event on July 14, 2026, and disclosed two pipeline additions: SNDX-4321, an externally licensed EGFR inhibitor for non-small cell lung cancer, and SNDX-62122, a next-generation menin inhibitor selected for myelofibrosis. The filing furnishes the press release and presentation but gives no new financial results, and it sets out development timelines, including a Phase 2 axatilimab trial in IPF with topline data expected in 4Q26.
SNDX-4321: IND submission expected by end of 2026 and Phase 1 trial in EGFR-mutated NSCLC planned for 2027; Syndax holds an exclusive worldwide license.
SNDX-62122 is the first candidate from Syndax's wholly owned next-generation menin inhibitor library; a revumenib Phase 1/2 proof-of-principle trial in myelofibrosis is expected to start in 4Q26.
Phase 2 trial of axatilimab in IPF remains on track for topline data in 4Q26.
Presentation states Revuforj and Niktimvo were each annualizing at about $200 million as of 1Q26.
Diodes Incorporated agreed on July 10, 2026, to acquire ElevATE Semiconductor, a San Diego fabless chip designer for automated test equipment, through a merger. The base price is $250.0 million in cash, subject to adjustments, plus up to $50.0 million in earnout payments tied to 2027 through 2030 revenue and gross margin targets. The deal is subject to closing conditions including HSR Act clearance and is expected to close in the second half of 2026.
Base purchase price of $250.0 million in cash, subject to customary adjustments for cash, debt, transaction costs, taxes and working capital
Earnout of up to $50.0 million based on post-closing revenue and gross margin thresholds for calendar years 2027 through 2030
Diodes expects ElevATE to add approximately $50 million of revenue in the first twelve months after closing
Expected close in the second half of 2026, subject to regulatory approvals including the HSR Act waiting period
Fastenal reported second-quarter 2026 results with net sales up 14.7% to $2.39 billion and net income up 15.9% to $383 million, or $0.33 per diluted share. Operating margin held at 21.0%, and operating cash flow fell 4.6% to $266 million as receivables grew, which the company attributed to strong sales growth late in the quarter.
Net sales were $2.39 billion, up 14.7% from $2.08 billion in the second quarter of 2025, with daily sales up 14.7%.
Net income was $383 million, up 15.9%, and diluted EPS was $0.33 versus $0.29 a year earlier.
Operating cash flow was $266 million, down 4.6%, or 69.4% of net income versus 84.4% a year earlier.
Shareholders received $305.1 million in dividends and share repurchases, or 79.7% of net income.
Virtu preliminarily estimated second-quarter 2026 trading income, net of $857 million, up from $653 million, while net income was $285 million, down from $293 million. Normalized Adjusted EPS rose to $1.82 from $1.53, but the estimates are unaudited and may change before final results on July 30, 2026. The same day, the company began marketing a $400 million add-on to its term loans, which would raise the term loan balance to $1,930 million.
Net income of $285 million vs. $293 million in Q2 2025; basic and diluted EPS of $1.63
Normalized Adjusted EPS of $1.82 vs. $1.53; Adjusted EBITDA of $437 million vs. $369 million
Trading income, net of $857 million vs. $653 million; Adjusted Net Trading Income of $718 million vs. $568 million
$400 million term loan add-on; commitments due July 16, 2026; final Q2 results due July 30, 2026
HCA Healthcare preliminarily reported second-quarter 2026 revenues of $20.230 billion and net income of $1.699 billion, or $7.62 per diluted share, both up from the year-earlier quarter. The company also lowered its 2026 net income and EPS guidance, citing a payer mix shift from health insurance exchange coverage losses, which shareholders should weigh against the stronger quarter. The preliminary figures are unaudited and subject to final quarterly closing procedures.
Q2 2026 revenues about $20.230 billion vs. $18.605 billion in Q2 2025; net income $1.699 billion ($7.62 per diluted share) vs. $1.653 billion ($6.83).
2026 diluted EPS guidance lowered to $28.70 to $30.50 from $29.10 to $31.50; net income guidance lowered to $6.300 billion to $6.700 billion from $6.495 billion to $7.035 billion.
Q2 unfavorable payer mix impact from exchange coverage losses estimated at about $400 million, partly offset by about $400 million of incremental Medicaid Supplemental Payment Program benefit.
Second-quarter earnings call scheduled for Friday, July 24, 2026, at 9:00 a.m. Central Time.
Bread Financial said Chief Commercial Officer Valerie Greer will retire on or around February 19, 2027, and that Dennis McCarthy will be promoted to Executive Vice President and Chief Revenue Officer in early September. Greer's retirement agreement provides a $945,000 cash payment and continued salary until her retirement date, and no new equity grants.
Valerie Greer, EVP and Chief Commercial Officer, will retire on or around February 19, 2027, and remain with the company through February 2027 for transition.
Retirement agreement dated July 8, 2026 includes a $945,000 cash payment, payable within 30 days of the retirement date, and her full-year 2026 annual cash incentive award.
Dennis McCarthy, who joined in 2021, becomes EVP and Chief Revenue Officer in early September, reporting to CEO Ralph Andretta.
AngioDynamics reported fiscal 2026 results for the year ended May 31, 2026, with pro forma net sales up 9.4% to $320.2 million and Med Tech sales up 18.4% to $150.0 million. The GAAP net loss widened to $36.7 million, or $0.88 per share, from $34.0 million, or $0.83, a year earlier, and the company issued fiscal 2027 guidance calling for net sales of $336.0 million to $341.0 million and adjusted loss per share of $0.29 to $0.24.
Fourth-quarter pro forma net sales were $86.6 million, up 8.0%, but the GAAP loss per share was $0.27 versus $0.15 a year earlier.
Full-year adjusted EBITDA was $13.2 million, compared with $7.6 million in the prior year.
Fiscal 2027 guidance: net sales of $336.0 million to $341.0 million and adjusted EPS of ($0.29) to ($0.24), compared with fiscal 2026 adjusted loss per share of $0.24.
The company ended fiscal 2026 with $53.9 million in cash and states it has a debt-free balance sheet.
Goldman Sachs reported second-quarter 2026 net revenues of $20.34 billion and net earnings of $6.63 billion, compared with $14.58 billion in revenue for the same quarter of 2025. Diluted EPS was $20.98, up from $10.91 a year earlier, and the board raised the quarterly dividend to $5.00 per share from $4.50 starting in the third quarter, which matters to shareholders because it increases cash returned to them.
Net revenues were $20.34 billion, up 39% from the second quarter of 2025 and 18% from the first quarter of 2026.
Diluted EPS was $20.98 versus $10.91 a year earlier; net earnings were $6.63 billion.
Quarterly dividend increased to $5.00 per share from $4.50, payable September 29, 2026 to holders of record on September 1, 2026.
Operating expenses rose 26% year over year to $11.67 billion; the firm returned $5.36 billion to common shareholders during the quarter.
IBM released selected preliminary second-quarter 2026 results, saying its final figures could differ slightly. Revenue rose 1% to $17.2 billion, but Infrastructure revenue fell 7% and GAAP diluted EPS declined 2% to $2.27, while operating (non-GAAP) EPS rose 5% to $2.93. CEO Arvind Krishna said the quarter was below the company's expectations, mainly because numerous large deals failed to close on the expected timelines.
Revenue of $17.2 billion, up 1%; Software up 5%, Consulting flat, Infrastructure down 7%
GAAP diluted EPS of $2.27, down 2%; operating (non-GAAP) EPS of $2.93, up 5%
GAAP gross profit margin 57.7%, down 100 basis points; GAAP pre-tax income margin 14.4%, down 90 basis points
Management will discuss full-year expectations on the conference call on July 22, 2026, at 5:00 p.m. ET
Bank of America reported second quarter 2026 net income of $9.1 billion, or $1.21 per diluted share, up from $7.2 billion, or $0.90 per share, a year earlier. Revenue rose 15% to $31.6 billion, and the company returned $8.0 billion to shareholders through dividends and share repurchases during the quarter.
Net income of $9.1 billion versus $7.2 billion in 2Q25, up 27%
Diluted EPS of $1.21 versus $0.90 a year earlier, up 34%
Revenue of $31.6 billion, up 15%; noninterest expense of $18.6 billion, up 8%
Returned $8.0 billion to shareholders: $2.0 billion in dividends and $6.0 billion in common stock repurchases
JPMorgan Chase reported second-quarter 2026 net income of $21.2 billion, or $7.70 per diluted share, up from $15.0 billion, or $5.24 per share, a year earlier. The results include a $4.6 billion net gain on Visa shares and $1.0 billion of gains on certain equity investments; excluding these significant items, net income was $16.9 billion, or $6.14 per share, which the filing says is up 13%.
Reported net revenue was $57.3 billion, up 28% from $44.9 billion in the second quarter of 2025; managed revenue was $58.0 billion, up 27%.
Noninterest expense rose 15% to $27.3 billion, and the provision for credit losses was $2.5 billion.
The Firm paid a common dividend of $1.50 per share ($4.0 billion) and made $6.2 billion of net common stock repurchases in the quarter.
Book value per share was $133.01 at June 30, 2026, up 9% from a year earlier; the filing does not include updated guidance.
Wells Fargo reported second quarter 2026 net income of $6.4 billion, or $2.00 per diluted share, up from $1.60 a year earlier, on total revenue of $22.6 billion, up 9%. The company also said it repurchased $3.0 billion of common stock in the quarter and expects its third quarter 2026 dividend to rise to $0.50 per share from $0.45, subject to board approval.
Diluted EPS of $2.00 vs. $1.60 in the second quarter of 2025, up 25%
Total revenue of $22,622 million, up 9% from a year earlier; noninterest expense up 2% to $13,661 million
Repurchased 37.4 million shares, or $3.0 billion, of common stock in the second quarter
Third quarter 2026 dividend expected at $0.50 per share, up from $0.45; CET1 ratio was 10.3% at June 30, 2026
Alto Neuroscience entered into an underwriting agreement on July 13, 2026, to sell 3,776,436 shares of common stock at $26.48 per share in a registered direct offering, with estimated net proceeds of approximately $93.9 million. The company plans to use the proceeds with its existing cash to accelerate ALTO-207 development, including an additional planned Phase 3 trial in treatment-resistant depression. The sale adds new shares outstanding, which dilutes existing holders, and closing is expected July 14, 2026.
Shares offered: 3,776,436 common shares at $26.48 each
Estimated net proceeds: approximately $93.9 million, after underwriting discounts and offering expenses
Use of proceeds: ALTO-207 clinical development, including an additional Phase 3 trial in treatment-resistant depression, and general working capital
Expected closing: July 14, 2026, subject to customary conditions; BofA Securities is representative
SemiLEDs reported preliminary results for the fiscal third quarter ended May 31, 2026, with revenue of $9.1 million, up from $1.1 million in the prior quarter, and GAAP net income of $1.5 million, or $0.18 per diluted share, compared with a net loss of $603 thousand in the prior quarter. The company said the revenue increase reflected higher buy-sell equipment purchase orders and that it anticipates more such orders in the fourth quarter of fiscal 2026. The filing also lists an Item 4.01 auditor change, but the text provided does not describe it.
Q3 fiscal 2026 revenue was $9.1 million, compared with $1.1 million in Q2 fiscal 2026.
GAAP net income attributable to stockholders was $1.5 million, or $0.18 per diluted share, versus a net loss of $603 thousand, or $(0.07) per share, in Q2.
GAAP gross margin rose to 27% from 1%; cash and cash equivalents were $6.0 million at May 31, 2026, versus $4.0 million at February 28, 2026.
The 8-K includes Item 4.01 (Auditor Change), but the filing text provided does not give details of the change.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.